|

Home
About Diabetes
Complications
Warning Signs
Screening Test
Donate Now
E-Lerts™
Index
Latest News
Diabetes Terms
Health & Fitness
Online Press Center
Meet Mr. Diabetes®
Wake Up And Walk®
Tour
Support Groups
Headlines & Stories
About Us - Contact
Info
Links
| |
FDA Issues Nationwide
Alert for "Liqiang 4" Due to Potential Health Risk
posted July 22, 2005
Warning consumers not to take
Liqiang 4 Dietary Supplement Capsules because they contain glyburide – a drug
that could have serious, life-threatening consequences in some people.
Glyburide is a drug used to lower blood sugar, and is safe and effective when
used as labeled in FDA-approved medications. People who have low blood sugar or
those with diabetes can receive dangerously high amounts of glyburide by
consuming Liqiang 4. Consumers should immediately stop using these products and
seek medical attention, especially if they are currently being treated with
diabetes drugs or if they have symptoms of fatigue, excessive hunger, profuse
sweating, or numbness of the extremities. Consumers who have this product should
dispose of it immediately.
The product is sold as part of a shrink-wrapped two bottle set. The product is
manufactured by Liqiang Research Institute, China, and marketed throughout the
United States in herbal stores and through mail order by Bugle International of
Northridge CA.
The FDA learned of the potential problem through an anonymous consumer complaint
and followed up with testing that revealed the presence of glyburide in this
product.
The product has also been termed "Liqiang Xiao Ke Ling" (Liqiang Thirst
Quenching Efficacious) in ads in Chinese language publications which also
promote it as useful for the control of diabetes and being derived from only
natural ingredients.
FDA encourages consumers, health care providers, and caregivers to report any
adverse events related to this product to MedWatch, the FDA's voluntary
reporting program at 1-800-FDA-1088; by FAX at 1-800-FDA-0178; by mail to
MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD,
20857-9787; or online at
www.fda.gov/medwatch/report.htm.
Source: Diabetes In Control.com.
News Article Index
|